Taiwo Kotila

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1127704/publications.pdf

Version: 2024-02-01

1163117 1058476 23 212 8 14 citations h-index g-index papers 23 23 23 301 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Good practice statements for antithrombotic therapy in the management of COVIDâ€19: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 2226-2236.	3.8	23
2	Association of the ABO blood group with SARSâ€CoVâ€2 infection in a community with low infection rate. Vox Sanguinis, 2021, 116, 910-915.	1.5	7
3	The Interaction of Sickle Cell Trait and Anticardiolipin Antibodies in Venousthromboembolism. Blood, 2021, 138, 4261-4261.	1.4	1
4	Acute leukemia in sickle cell disease patients in a tertiary health facility in Nigeria: a case series. African Health Sciences, 2020, 20, 1304-1312.	0.7	5
5	The effect of the coinheritance of Glucose-6-phosphate dehydrogenase deficiency on the severity of sickle cell disease. Nigerian postgraduate medical journal, The, 2019, 26, 118.	0.4	5
6	Sickle Cell Disease Clinical Trials and Phenotypes. Journal of Tropical Diseases, 2018, 06, 259.	0.1	1
7	Haematological and fibrinolytic status of Nigerian women with post-partum haemorrhage. BMC Pregnancy and Childbirth, 2018, 18, 143.	2.4	28
8	Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): a single-centre, randomised, double-blind, placebo-controlled trial. Wellcome Open Research, 2018, 3, 100.	1.8	24
9	Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle ell disease patients and healthy controls in Nigeria. Pharmacology Research and Perspectives, 2016, 4, e00252.	2.4	1
10	Sickle Cell Trait: A Benign State?. Acta Haematologica, 2016, 136, 147-151.	1.4	15
11	Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): protocol and statistical analysis plan for a randomized controlled trial. Wellcome Open Research, 2016, 1, 31.	1.8	8
12	Guidelines for teh diagnosis of the haemoglobinopathies in Nigeria. Annals of Ibadan Postgraduate Medicine, 2011, 8, 25-9.	0.1	10
13	Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls. Journal of Clinical Pharmacy and Therapeutics, 2010, 35, no-no.	1.5	5
14	Molecular and Contextual Markers of Hepatitis C Virus and Drug Abuse. Molecular Diagnosis and Therapy, 2009, 13, 153-179.	3.8	5
15	Beta thalassaemia trait in western Nigeria. African Health Sciences, 2009, 9, 46-8.	0.7	12
16	Molecular and contextual markers of hepatitis C virus and drug abuse. Molecular Diagnosis and Therapy, 2009, 13, 153-79.	3.8	3
17	Trends in Transfusion-Transmitted Viral Infections from 2001 to 2006 in Ibadan, Nigeria. Intervirology, 2008, 51, 427-431.	2.8	28
18	HODGKIN LYMPHOMA IN A CHILD WITH SICKLE CELL ANEMIA. Pediatric Hematology and Oncology, 2007, 24, 531-535.	0.8	7

Taiwo Kotila

#	Article	lF	CITATIONS
19	When the inheritance of two heterozygote state become a diagnostic problem: Misdiagnosis of the sickle cell trait. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria, 2007, 16, 173-6.	0.1	7
20	Liver dysfunction in steady state sickle cell disease. Annals of Hepatology, 2005, 4, 261-3.	1.5	3
21	Haemoglobin F levels in healthy Nigerian adults. West African Journal of Medicine, 2004, 22, 143-5.	0.1	5
22	Survival advantage in female patients with sickle cell anaemia. East African Medical Journal, 2001, 78, 373.	0.0	7
23	Hodgkin's disease after treatment for Burkitt's lymphoma: case report. East African Medical Journal, 2001, 78, 334-6.	0.0	2